Rite Aid (RAD) Comps Rose 4.8% in Jan.
Get Alerts RAD Hot Sheet
Revenue Growth %: -100.0%
Financial Fact:
Total costs and expenses: 8B
Today's EPS Names:
SHIM, KOD, HEWA, More
Join SI Premium – FREE
Rite Aid (NYSE: RAD) announced sales results for January.
Monthly SalesFor the four weeks ended Jan. 24, 2015, same store sales increased 4.8 percent over the prior-year period. January front-end same store sales increased 2.9 percent. Pharmacy same store sales, which included an approximate 114 basis points negative impact from new generic introductions, increased 5.7 percent. Prescription count at comparable stores increased 3.5 percent over the prior-year period.
Total drugstore sales for the four-week period increased 4.3 percent to $2.026 billion compared to $1.943 billion for the same period last year. Prescription sales accounted for 70.3 percent of drugstore sales, and third party prescription sales represented 97.3 percent of pharmacy sales.
Year-to-DateSame store sales for the 47-week period ended Jan. 24, 2015 increased 4.4 percent over the prior-year period. Front-end same store sales increased 1.2 percent while pharmacy same store sales increased 5.9 percent. Prescription count at comparable stores increased 3.6 percent over the prior-year period.
Total drugstore sales for the 47 weeks ended Jan. 24, 2015 increased 3.9 percent with sales of $23.789 billion compared to $22.896 billion for the same period last year. Prescription sales represented 68.7 percent of total drugstore sales, and third party prescription sales represented 97.5 percent of pharmacy sales.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Walgreens Boots Alliance (WBA) tops Q2 expectations, narrows full-year profit forecast
- 22nd Century Group (XXII) Reports Q4 Revenue of $7.4M, Net Loss of $22.1M
- Carnival Corp. (CCL) tops Q1 expectations as booking volumes 'hit an all-time high'
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!